BlackRock
SKYE icon

BlackRock’s Skye Bioscience SKYE Stock Holding History

BlackRock’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Sell
29,109
-6,657
-19% -$41.9K ﹤0.01% 4884
2026
Q1 		$176K Buy
35,766
+536
+2% +$3.49K ﹤0.01% 4807
2025
Q4 		$211K Buy
35,230
+247
+0.7% +$2.89K ﹤0.01% 4710
2025
Q3 		$1.1M Sell
34,983
-16,594
-32% -$501K ﹤0.01% 4266
2025
Q2 		$1.72M Sell
51,577
-98,635
-66% -$1.63M ﹤0.01% 4104
2025
Q1 		$1.91M Sell
150,212
-2,311
-2% -$50.5K ﹤0.01% 4010
2024
Q4 		$3.45M Buy
152,523
+3,334
+2% +$111K ﹤0.01% 3864
2024
Q3 		$4.67M Buy
149,189
+9,343
+7% +$419K ﹤0.01% 3722
2024
Q2 		$8.96M Buy
+139,846
New +$13.3M ﹤0.01% 3437

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's SKYE Position: Q2 2026 in Review

BlackRock reduced its Skye Bioscience (SKYE) stake by 19% in Q2 2026, selling an estimated $41.9K and leaving 29,109 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #4884.

BlackRock first reported a position in SKYE in Q2 2024 and has held it in 9 quarters since. The position peaked at $8.96M in Q2 2024. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • BlackRock held 29,109 shares of Skye Bioscience worth $161K as of Q2 2026.
  • BlackRock sold 6,657 Skye Bioscience shares in Q2 2026, an estimated $41.9K.
  • Skye Bioscience made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4884 holding.
  • BlackRock first reported a position in Skye Bioscience in Q2 2024 and has held it in 9 quarters since.
  • BlackRock's Skye Bioscience position peaked at $8.96M in Q2 2024.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.